Role of emmprin in endometrial cancer

Keiichiro Nakamura, Junichi Kodama, Atsushi Hongo, Yuji Hiramatsu

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Extracellular matrix metalloproteinase inducer (Emmprin/CD147) is a transmembrane glycoprotein that belongs to the immunoglobulin superfamily. Enriched on the surface of many tumor cells, emmprin promotes tumor growth, invasion, metastasis and angiogenesis. We evaluated the clinical importance of emmprin and investigated its role in endometrial cancer.Methods: Emmprin expression was examined in uterine normal endometrium, endometrial hyperplasia and cancer specimens by immunohistochemistry. In addition, the biological functions and inhibitory effects of an emmprin knockdown were investigated in HEC-50B and KLE endometrial cancer cell lines.Results: The levels of emmprin expression were significantly increased in the endometrial cancer specimens compared with the normal endometrium and endometrial hyperplasia specimens (p <0.05). The disease-free survival (DFS) and overall survival (OS) rates of patients with high emmprin expression were significantly higher than those of patients with low emmprin expression (DFS: p <0.001; OS: p <0.001). Emmprin knockdown by the siRNA led to cell proliferation, migration and invasion through TGF-β, EGF, NF-κB, VEGF, MMP-2, and MMP-9 expression, which in turn resulted in increased levels of E-cadherin and reduced levels of Vimentin and Snail in endometrial cancer.Conclusions: The present findings suggest that low emmprin expression might be a predictor of favorable prognosis in endometrial cancer patients, and that emmprin may represent a potential therapeutic target for endometrial cancer.

Original languageEnglish
Article number191
JournalBMC Cancer
Volume12
DOIs
Publication statusPublished - May 28 2012

Fingerprint

CD147 Antigens
Endometrial Neoplasms
Endometrial Hyperplasia
Endometrium
Matrix Metalloproteinases
Disease-Free Survival
Vimentin
Cadherins
Epidermal Growth Factor

Keywords

  • Emmprin
  • Endometrial cancer
  • Epithelial-mesenchymal transition
  • Potential therapeutic target
  • Predictor of favorable prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Role of emmprin in endometrial cancer. / Nakamura, Keiichiro; Kodama, Junichi; Hongo, Atsushi; Hiramatsu, Yuji.

In: BMC Cancer, Vol. 12, 191, 28.05.2012.

Research output: Contribution to journalArticle

Nakamura, Keiichiro ; Kodama, Junichi ; Hongo, Atsushi ; Hiramatsu, Yuji. / Role of emmprin in endometrial cancer. In: BMC Cancer. 2012 ; Vol. 12.
@article{98e74df2cc0242da83a8617f28f519c0,
title = "Role of emmprin in endometrial cancer",
abstract = "Background: Extracellular matrix metalloproteinase inducer (Emmprin/CD147) is a transmembrane glycoprotein that belongs to the immunoglobulin superfamily. Enriched on the surface of many tumor cells, emmprin promotes tumor growth, invasion, metastasis and angiogenesis. We evaluated the clinical importance of emmprin and investigated its role in endometrial cancer.Methods: Emmprin expression was examined in uterine normal endometrium, endometrial hyperplasia and cancer specimens by immunohistochemistry. In addition, the biological functions and inhibitory effects of an emmprin knockdown were investigated in HEC-50B and KLE endometrial cancer cell lines.Results: The levels of emmprin expression were significantly increased in the endometrial cancer specimens compared with the normal endometrium and endometrial hyperplasia specimens (p <0.05). The disease-free survival (DFS) and overall survival (OS) rates of patients with high emmprin expression were significantly higher than those of patients with low emmprin expression (DFS: p <0.001; OS: p <0.001). Emmprin knockdown by the siRNA led to cell proliferation, migration and invasion through TGF-β, EGF, NF-κB, VEGF, MMP-2, and MMP-9 expression, which in turn resulted in increased levels of E-cadherin and reduced levels of Vimentin and Snail in endometrial cancer.Conclusions: The present findings suggest that low emmprin expression might be a predictor of favorable prognosis in endometrial cancer patients, and that emmprin may represent a potential therapeutic target for endometrial cancer.",
keywords = "Emmprin, Endometrial cancer, Epithelial-mesenchymal transition, Potential therapeutic target, Predictor of favorable prognosis",
author = "Keiichiro Nakamura and Junichi Kodama and Atsushi Hongo and Yuji Hiramatsu",
year = "2012",
month = "5",
day = "28",
doi = "10.1186/1471-2407-12-191",
language = "English",
volume = "12",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Role of emmprin in endometrial cancer

AU - Nakamura, Keiichiro

AU - Kodama, Junichi

AU - Hongo, Atsushi

AU - Hiramatsu, Yuji

PY - 2012/5/28

Y1 - 2012/5/28

N2 - Background: Extracellular matrix metalloproteinase inducer (Emmprin/CD147) is a transmembrane glycoprotein that belongs to the immunoglobulin superfamily. Enriched on the surface of many tumor cells, emmprin promotes tumor growth, invasion, metastasis and angiogenesis. We evaluated the clinical importance of emmprin and investigated its role in endometrial cancer.Methods: Emmprin expression was examined in uterine normal endometrium, endometrial hyperplasia and cancer specimens by immunohistochemistry. In addition, the biological functions and inhibitory effects of an emmprin knockdown were investigated in HEC-50B and KLE endometrial cancer cell lines.Results: The levels of emmprin expression were significantly increased in the endometrial cancer specimens compared with the normal endometrium and endometrial hyperplasia specimens (p <0.05). The disease-free survival (DFS) and overall survival (OS) rates of patients with high emmprin expression were significantly higher than those of patients with low emmprin expression (DFS: p <0.001; OS: p <0.001). Emmprin knockdown by the siRNA led to cell proliferation, migration and invasion through TGF-β, EGF, NF-κB, VEGF, MMP-2, and MMP-9 expression, which in turn resulted in increased levels of E-cadherin and reduced levels of Vimentin and Snail in endometrial cancer.Conclusions: The present findings suggest that low emmprin expression might be a predictor of favorable prognosis in endometrial cancer patients, and that emmprin may represent a potential therapeutic target for endometrial cancer.

AB - Background: Extracellular matrix metalloproteinase inducer (Emmprin/CD147) is a transmembrane glycoprotein that belongs to the immunoglobulin superfamily. Enriched on the surface of many tumor cells, emmprin promotes tumor growth, invasion, metastasis and angiogenesis. We evaluated the clinical importance of emmprin and investigated its role in endometrial cancer.Methods: Emmprin expression was examined in uterine normal endometrium, endometrial hyperplasia and cancer specimens by immunohistochemistry. In addition, the biological functions and inhibitory effects of an emmprin knockdown were investigated in HEC-50B and KLE endometrial cancer cell lines.Results: The levels of emmprin expression were significantly increased in the endometrial cancer specimens compared with the normal endometrium and endometrial hyperplasia specimens (p <0.05). The disease-free survival (DFS) and overall survival (OS) rates of patients with high emmprin expression were significantly higher than those of patients with low emmprin expression (DFS: p <0.001; OS: p <0.001). Emmprin knockdown by the siRNA led to cell proliferation, migration and invasion through TGF-β, EGF, NF-κB, VEGF, MMP-2, and MMP-9 expression, which in turn resulted in increased levels of E-cadherin and reduced levels of Vimentin and Snail in endometrial cancer.Conclusions: The present findings suggest that low emmprin expression might be a predictor of favorable prognosis in endometrial cancer patients, and that emmprin may represent a potential therapeutic target for endometrial cancer.

KW - Emmprin

KW - Endometrial cancer

KW - Epithelial-mesenchymal transition

KW - Potential therapeutic target

KW - Predictor of favorable prognosis

UR - http://www.scopus.com/inward/record.url?scp=84861445963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861445963&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-12-191

DO - 10.1186/1471-2407-12-191

M3 - Article

C2 - 22640183

AN - SCOPUS:84861445963

VL - 12

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 191

ER -